Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biocapital symbols : INCY save search
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $21.51 -0.97% 200K
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XNCR | $19.08 -5.12% 170K
|
Health Technology
|
| O: -1.55%
H: 2.76%
C: 1.84%
MOR | $17.985 -0.19% 330K
|
Health Technology
|
| O: 0.99%
H: 59.84%
C: 54.47%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
monjuvi global commercialization
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-01-23 (Crawled : 14:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.37%
H: 0.75%
C: 0.23%
report financial results
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | $13.235 0.42% 710K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $19.08 -5.12% 170K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | $17.985 -0.19% 330K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Incyte to Present at Upcoming Investor Conferences - October 18, 2023
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.23%
H: 1.1%
C: -0.42%
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
MGNX 4 | $16.86 -0.47% 360K
|
Health Technology
|
| O: 0.59%
H: 3.33%
C: 1.37%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.62%
H: 0.16%
C: -0.59%
congress
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
Published: 2023-09-29 (Crawled : 22:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: -1.85%
congress
Incyte to Present at Upcoming Investor Conferences - August 22, 2023
Published: 2023-08-22 (Crawled : 13:00) - biospace.com/
MS 3 d | $89.17 2.51% 13M
|
Finance
|
| O: -0.47%
H: 0.0%
C: 0.0%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.08%
H: 1.11%
C: -0.06%
Incyte to Present at Upcoming Investor Conferences - May 23, 2023
Published: 2023-05-23 (Crawled : 13:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.05%
H: 2.49%
C: 1.12%
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
TAK | $13.235 0.42% 710K
|
Health Technology
|
| O: -0.42%
H: 0.48%
C: 0.3%
XNCR | $19.08 -5.12% 170K
|
Health Technology
|
| O: -0.63%
H: 0.15%
C: -1.78%
MOR | $17.985 -0.19% 330K
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: -3.15%
MGNX 4 | $16.86 -0.47% 360K
|
Health Technology
|
| O: -1.62%
H: 2.47%
C: -6.58%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -9.64%
H: 5.99%
C: 2.76%
financial results
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
Published: 2023-05-01 (Crawled : 22:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.3%
H: 1.49%
C: 0.95%
opzelura rapid dermatitis trial results
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
Published: 2023-04-20 (Crawled : 20:00) - biospace.com/
ARVL | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -12.76%
H: 0.0%
C: 0.0%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.23%
H: 0.87%
C: 0.29%
opzelura approval treatment
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Published: 2023-03-22 (Crawled : 22:00) - biospace.com/
MGNX 4 | $16.86 -0.47% 360K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -6.28%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.04%
H: 0.46%
C: -1.71%
fda approval cell treatment
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-14 (Crawled : 01:00) - biospace.com/
NVSEF | $93.6375 82K
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: 0.31%
XNCR | $19.08 -5.12% 170K
|
Health Technology
|
| O: 1.2%
H: 0.17%
C: -1.67%
MOR | $17.985 -0.19% 330K
|
Health Technology
|
| O: -1.79%
H: 3.39%
C: 3.39%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.18%
H: 1.06%
C: 0.94%
meeting
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.3%
H: 0.14%
C: -0.53%
treatment chmp positive
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
Published: 2023-02-16 (Crawled : 07:00) - biospace.com/
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -1.2%
H: 0.58%
C: -1.49%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.16%
H: 0.29%
C: -1.56%
il23 trial psoriasis
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
SNYNF | $92.966 630
|
Health Technology
|
| O: -2.5%
H: 0.0%
C: 0.0%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -0.4%
H: 0.75%
C: -1.21%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.21%
H: 1.66%
C: 1.46%
drug tyvyt china
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: -0.19%
H: 1.54%
C: 0.72%
report financial results
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
immunotherapy meeting cancer
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: -5.85%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
incb9928 collaboration trial therapeutics tumors agreement
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.